1461 citations
,
March 2004 in “Annals of oncology” This study found that in first-line treatment of metastatic breast cancer, pegylated liposomal doxorubicin (PLD) provided similar progression-free survival to doxorubicin with significantly less cardiotoxicity.
522 citations
,
January 2001 in “Cancer investigation” This review describes the unique pharmacological profile and clinical applications of pegylated liposomal doxorubicin, emphasizing its role in Kaposi's sarcoma and recurrent ovarian cancer, but reports no new clinical results.
108 citations
,
December 2003 in “Clinical breast cancer” The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.
63 citations
,
February 2013 in “Human cell” In this study using an animal model, researchers found that PEGL-DOX, unlike DOX, causes Hand-Foot Syndrome due to reactive oxygen species interacting with skin tissue, leading to skin-specific inflammatory responses.
June 2026 in “Cancer Research Communications” In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.